Tamyra A. Toole
General Counsel chez RUBIUS THERAPEUTICS
Profil
Tamyra A.
Toole is currently the Vice President-Regulatory Affairs at Rubius Therapeutics, Inc. She previously worked as the Senior Director-Regulatory Affairs at NitroMed, Inc. from 2005 to 2008 and as the VP-Regulatory Affairs & Quality Assurance at Infinity Pharmaceuticals, Inc. from 2008 to 2017.
Ms. Toole has a graduate degree from The Catholic University of America and an undergraduate degree from Villanova University.
Postes actifs de Tamyra A. Toole
| Sociétés | Poste | Début |
|---|---|---|
| RUBIUS THERAPEUTICS | General Counsel | 01/06/2018 |
Anciens postes connus de Tamyra A. Toole
| Sociétés | Poste | Fin |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | General Counsel | 01/01/2017 |
NitroMed, Inc.
 NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | General Counsel | 01/05/2008 |
Formation de Tamyra A. Toole
| The Catholic University of America | Graduate Degree |
| Villanova University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Health Technology |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
